Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026)
Phathom Pharmaceuticals (PHAT) posted quarterly Cash from Investing Activities of -$44000.0 for Q2 2026, up 54.64% year-over-year from -$28453.3 in Q2 2025, and up 27.87% quarter-over-quarter from -$61000.0 in Q1 2026.
Powered by 
Analysis
Phathom Pharmaceuticals (PHAT) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Phathom Pharmaceuticals (PHAT) has reported Cash from Investing Activities for 8 consecutive years, with -$44000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Cash from Investing Activities rose 54.64% year-over-year to -$44000.0; the TTM figure through Jun 2026 stood at -$219000.0 (down 33.54% YoY), while the FY2025 annual figure was -$229000.0, down 69.63% from the prior year.
- Cash from Investing Activities advanced to -$44000.0 in Q2 2026 per PHAT's latest filing, from -$61000.0 in the prior quarter.
- Across five years, Cash from Investing Activities topped out at -$5000.0 in Q4 2024 and bottomed at -$939000.0 in Q3 2023.
- Historically, Cash from Investing Activities has averaged -$174666.7 across 5 years, with a median of -$64000.0 in 2022.
- Annual changes were most pronounced in 2024 — Cash from Investing Activities soared 98.95% — and 2025, when it plunged 1640.0%.
- Phathom Pharmaceuticals' Cash from Investing Activities stood at -$412000.0 in 2022, then decreased by 15.29% to -$475000.0 in 2023, then jumped by 98.95% to -$5000.0 in 2024, then slumped by 1640.0% to -$87000.0 in 2025, then soared by 49.43% to -$44000.0 in 2026.
- Business Quant data shows PHAT's Cash from Investing Activities at -$44000.0 in Q2 2026, -$61000.0 in Q1 2026, and -$87000.0 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 329.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -1.66 Bn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | -49.35 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | -363.46 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -229.72 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 24.51 Mn |
| 10 | Phathom Pharmaceuticals | 796.85 Mn | 611.51 Mn | 59.18 Mn | -44,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44,000.00 |
| Mar 31, 2026 | -61,000.00 |
| Dec 31, 2025 | -87,000.00 |
| Sep 30, 2025 | -27,000.00 |
| Jun 30, 2025 | -97,000.00 |
| Mar 31, 2025 | -18,000.00 |
| Dec 31, 2024 | -5,000.00 |
| Sep 30, 2024 | -44,000.00 |
| Jun 30, 2024 | -46,000.00 |
| Mar 31, 2024 | -40,000.00 |
| Dec 31, 2023 | -475,000.00 |
| Sep 30, 2023 | -939,000.00 |
| Jun 30, 2023 | -6,000.00 |
| Mar 31, 2023 | -214,000.00 |
| Dec 31, 2022 | -412,000.00 |
| Sep 30, 2022 | -134,000.00 |
| Jun 30, 2022 | -428,000.00 |
| Mar 31, 2022 | -67,000.00 |
| Dec 31, 2021 | -100,000.00 |
| Sep 30, 2021 | -14,000.00 |